Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02351856 · ClinicalTrials.gov registry record · Phase 2
A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
A Phase 2 study of LMNA-Related Dilated Cardiomyopathy, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 4
- Study locations
NCT02351856 is a Phase 2 study of LMNA-Related Dilated Cardiomyopathy that has completed, run by Pfizer. The registered enrollment target is 8 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT02351856, a Phase 2 study of LMNA-Related Dilated Cardiomyopathy, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a rollover study designed to investigate the safety and effectiveness of investigational study drug ARRY-371797 in patients who previously received ARRY-371797 in a study for patients with LMNA-related dilated cardiomyopathy sponsored by Array BioPharma and may, in the Investigator's opinion, derive benefit from continued treatment.
Conditions Studied
Interventions
- DRUG ARRY-371797, p38 inhibitor, oral
Study Locations (4)
Colorado
- University of Colorado Hospital - Aurora
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Brigham & Women's Hospital - Boston
Wisconsin
- Meriter Wisconsin Heart - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-02-02 |
| Est. Completion | 2020-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02351856
The ClinicalTrials.gov registry entry for NCT02351856 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with LMNA-Related Dilated Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which ARRY-371797, p38 inhibitor, oral is the first listed.
NCT02351856 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Colorado, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02351856 about?
NCT02351856 is a clinical study titled "A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy". This is a rollover study designed to investigate the safety and effectiveness of investigational study drug ARRY-371797 in patients who previously received ARRY-371797 in a study for patients with LMNA-related dilated cardiomyopathy sponsored by Array BioPharma and may, in the Investigator's opinion...
What is the current status of trial NCT02351856?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2015-02-02. Estimated completion is 2020-12-21.
What conditions does trial NCT02351856 study?
This clinical trial studies the following conditions: LMNA-Related Dilated Cardiomyopathy.
What interventions are being tested in trial NCT02351856?
The interventions under investigation include: ARRY-371797, p38 inhibitor, oral (DRUG).
Who is sponsoring clinical trial NCT02351856?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02351856 being conducted?
This trial has 4 study locations across Colorado, Maryland, Massachusetts, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.